With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.163765-44-4,(R)-1-Boc-3-Methylpiperazine,as a common compound, the synthetic route is as follows.
Example 14; l-Methyl-2-[(2R)-2-methyl-4-(quinoline-2-carbonyl)-piperazin-l-yl]- 1eta- [4,4′]bipyrimidinyl-6-one; (3R)-3’Methvl-4′(l-methvl’6-oxo-l,6-dihvdro-[4,4′]bipvrimidinvl-2’vl)-piperazine-l’car boxvlic acid tert-butvl ester; A solution of 2-chloro-3-methyl-6-(pyrimidin-4-yl)-3H-pyrimidin-4-one (5.3 g, 24 mmol), fer^butyl (Si^-S-methylpiperazine-l-carboxylate (5.0 g, 25 mmol) and triethylamine (7.6 g, 75 mmol) in N-methyl”2-pyrrolidone (25 ml) was stirred for 6 hours at 90 0C. The solution was partitioned between water and ethyl acetate, and the organic layer was washed with water, brine, dried over sodium sulfate, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (eluent; ethyl acetate) to afford (3R)-3-methyl-4-(l-methyl-6-oxo-l,6- dihydro-[4,4′]bipyrimidinyl-2-yl)-piperazine”l-carboxylic acid tert-butyl ester (6.9 g, 71 %)..1H NMR; 1.28 (3H, d, J= 7.0 Hz), 1.51 (9H, brs), 3.29-3.52 (4H, m), 3.55 (3H, s), 3.71 (IH, dd, J= 3.9, 13.3 Hz), 3.81-4.02 (2H, m), 7.29 (IH, s), 8.16 (IH, dd, J= 1.6, 5.5 Hz), 8.88 (IH, d, J= 4.7 Hz), 9.25 (IH, s) (CDCl3) MS; [M++ 1] = 387 ., 163765-44-4
As the paragraph descriping shows that 163765-44-4 is playing an increasingly important role.
Reference:
Patent; MITSUBISHI PHARMA CORPORATION; SANOFI-AVENTIS; WO2007/119463; (2007); A1;,
Piperazine – Wikipedia
Piperazines – an overview | ScienceDirect Topics